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Objectives: A whole-genome screen at sub-gene resolution was performed to identify candidate loci that con-
tribute to enhanced or diminished ciprofloxacin susceptibility in Salmonella enterica serovar Typhi.
Methods: A pool of over 1 million transposon insertion mutants of an S. Typhi Ty2 derivative were grown in a
sub-MIC concentration of ciprofloxacin, or without ciprofloxacin. Transposon-directed insertion site sequencing
(TraDIS) identified relative differences between the mutants that grew following the ciprofloxacin treatment
compared with the untreated mutant pool, thereby indicating which mutations contribute to gain or loss of
ciprofloxacin susceptibility.
Results: Approximately 88% of the S. Typhi strain’s 4895 annotated genes were assayed, and at least 116 were
identified as contributing to gain or loss of ciprofloxacin susceptibility. Many of the identified genes are known to
influence susceptibility to ciprofloxacin, thereby providing method validation. Genes were identified that were
not known previously to be involved in susceptibility, and some of these had no previously known phenotype.
Susceptibility to ciprofloxacin was enhanced by insertion mutations in genes coding for efflux, other surface-
associated functions, DNA repair and expression regulation, including phoP, barA and marA. Insertion mutations
that diminished susceptibility were predominantly in genes coding for surface polysaccharide biosynthesis and
regulatory genes, including slyA, emrR, envZ and cpxR.
Conclusions: A genomics approach has identified novel contributors to gain or loss of ciprofloxacin susceptibility
in S. Typhi, expanding our understanding of the impact of fluoroquinolones on bacteria and of mechanisms that
may contribute to resistance. The data also demonstrate the power of the TraDIS technology for antibacterial
research.
Introduction
Salmonella enterica subsp. enterica serovar Typhi causes tens of
millions of cases of typhoid fever, resulting in over 100 000 deaths
annually.1 These are likely to be underestimates because of the
predominance of typhoid fever in low- to middle-income countries
where there is often a paucity of diagnostic facilities2 capable of
differentiating typhoid fever from other, clinically similar, febrile
diseases.3 Since the introduction of chloramphenicol for the treat-
ment of typhoid, the spread of antibiotic-resistant S. Typhi strains
has led to treatment failures.4 The emergence of MDR strains asso-
ciated with the acquisition of plasmids5 and the emergence of the
H58 haplotype6,7 and of XDR strains has led to typhoid fever that
fails to respond to treatment with any of the antibiotics commonly
used for treatment, including chloramphenicol, sulfamethoxazole/
trimethoprim, ampicillin/amoxicillin, ciprofloxacin and ceftriax-
one.8,9 Furthermore, XDR typhoid fever is now spreading in
Pakistan.10
Ciprofloxacin (and other fluoroquinolone antibacterials) target
the topoisomerase enzymes, DNA gyrase and topoisomerase IV,
which are essential functions required for the maintenance of
appropriate levels of DNA topology. In Escherichia coli and
Salmonella, resistance is multifactorial, but usually requires point
mutations leading to amino acid substitutions at Ser83 of the
DNA gyrase GyrA subunit.11 Alone, such mutations reduce
VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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susceptibility to fluoroquinolones and have resulted in prolonged
treatment times with increased shedding, and outright treatment
failures.6,12–15 However, high-level resistance requires further fac-
tors, such as additional mutations within the topoisomerase
genes, or is associated with those conferring reduced cell perme-
ability and increased antibiotic efflux, or acquisition of a quinolone
resistance determinant, such as qnr.8,11,16–18
It is likely that other mechanisms exist that contribute to
fluoroquinolone resistance in S. Typhi, which may be relevant to
other bacteria, and the application of transposon insertion
sequencing technologies, such as transposon-directed insertion
site sequencing (TraDIS),19–22 provides a way to identify these
other mechanisms. This involves growing a very large collection
of bacterial transposon insertion mutants as a pool under a
growth condition of interest. Within the population of mutants,
some will show a loss of susceptibility to the condition, and grow
more poorly, whilst others will show reduced susceptibility and
grow relatively faster. By determining nucleotide sequences
from the transposon insertions into the adjacent DNA and com-
paring them with a reference whole-genome nucleotide se-
quence, the sequence reads can pinpoint the locations of many
transposon insertions in the pool of mutants simultaneously.
The number of sequence reads generated at the different sites
provides a semi-quantitative measure of the numbers of
mutants and, by using at least several hundred thousand trans-
poson mutants, the whole of the non-essential bacterial gen-
ome may be assayed down to a resolution of, on average, a few
base pairs. Thus, TraDIS can measure changes in the population
of the transposon mutants in a condition of interest compared
with a standard control.21
In this manuscript, we describe the use of TraDIS to assay the S.
Typhi genome for genes involved in gain or loss of susceptibility to
ciprofloxacin in a strain that already harbours a gyrA mutation
resulting in a GyrA Ser83Phe amino acid substitution and exhibiting
reduced susceptibility to fluoroquinolones.16 Our data identify
many of these genes, including those already known and new
ones, thus providing clues as to which genes may mutate and con-
tribute to increased clinical resistance. In addition, mutations that
lead to a gain of susceptibility indicate that the products of these
genes are candidates for the development of antibacterials that
may restore susceptibility to ciprofloxacin.
To our knowledge, this is only the second whole-genome screen
to investigate the pathways to gain or loss of susceptibility to a
fluoroquinolone at this level of genome resolution in bacteria.23
Materials and methods
S. Typhi transposon mutant library
The transposon mutant library used for this study has been described previ-
ously and was estimated to consist of at least 1 million mini-Tn5 trans-
poson insertion mutants21 (for more details see the Supplementary data,
available at JAC Online). The mutant collection exists, and is used, as a sin-
gle pool split between experimental growth conditions, and the majority of
mutants each contain a single transposon insertion in the genome. The par-
ent strain, WT26 pHCM1, possesses a GyrA Ser83Phe substitution conferring
reduced susceptibility to fluoroquinolone antibiotics (MIC of ciprofloxacin
0.25 mg/L compared with 0.016 mg/L for the parent strain), and harbours
the multiple antibiotic resistance plasmid pHCM1. This strain has
attenuating deletion mutations in aroC, aroD and htrA, and requires supple-
mentation of LB broth with 0.004% phenylalanine, 0.004% tryptophan,
0.001% para-aminobenzoic acid, 0.001% dihydrobenzoic acid and 0.004%
tyrosine (‘aro mix’) to grow.16,24–26
Passage of the transposon mutant library pool
The S. Typhi transposon mutant pool (1%109 cfu) was grown in 100 mL of
LB broth ! aro mix, with or without 0.05 mg/L of ciprofloxacin (about 1=5 %
MIC)16 in duplicate. After overnight incubation at 37C, a second passage of
each of the four cultures was prepared similarly and inoculated with 1 mL
of the previous respective culture, and again incubated overnight at 37C,
to give growth amounting to a total of about 15 generations. Genomic DNA
was extracted from1%1010 cells from each culture using a genomic DNA
extraction buffer kit and Tip-100G columns (QIAGEN).
TraDIS sequencing and data analysis
Nucleotide sequences were generated from each extracted DNA sample
using the modified protocol described previously.21 This uses a custom
oligonucleotide sequencing primer which anneals to the nucleotides of
known sequence at the transposon end to generate nucleotide sequence
reads from the transposon into the adjacent target DNA for all of the trans-
poson mutants simultaneously. Nucleotide sequence reads (Table S1) were
compared with a reference genome nucleotide sequence that combined
the sequences of S. Typhi Ty2 (accession number AE014613) and plasmid
pHCM1 (accession number NC_003384), using the Bio-Tradis software
suite27 installed on CLIMB virtual machine servers.28 Nucleotide sequence
homology between a sequence read and the reference genome locates a
transposon insertion site, and the number of sequence reads that locate
with that site is a semi-quantitative measure of the copy number of
mutants present in the transposon mutant pool.
The mutant site and number of reads were compared with the genome
annotation to determine the number of reads that locate within each gene.
Comparison of the data of the controls with the ciprofloxacin-treated dupli-
cates using the Bio-Tradis analysis software toolkit gives the ratio of log2
fold change (log2FC), log2 counts per million (log2CPM) and P and q values
for each gene. The FC refers to the difference in the number of sequence
reads that locate with a gene between ciprofloxacin-treated and untreated
conditions. Thus, negative values indicate that insertion mutation in that
gene results in a gain in ciprofloxacin susceptibility and positive values a
loss. These data were filtered for genes that had log2 FC values 1.4 or
#1.4 (i.e. an increase or decrease of greater than 2.6-fold). CPM refers
to the number of reads per gene if the total number of nucleotide se-
quence reads generated for the sample had been 1 million. Genes with
sequence read values of log2 CPM <2.75 (less than 6) were discarded
from the data set. The data sets presented here have at least 13 million
associated sequence reads (Table S1). Thus, any gene represented by
fewer than 78 reads was excluded from the analysis. The P value is the
statistical probability of obtaining the result if the gene is not involved in
gain or loss of susceptibility to ciprofloxacin, and the q value is the
P value adjusted for the false discovery rate (the proportion of false posi-
tives expected from a test). Gene data filtered as above all had q values
of <0.00002. Genes within this data set are likely to contribute the most
to gain or loss of susceptibility to 0.05 mg/L ciprofloxacin and are
presented in Tables 1 and 2, but do not necessarily include all candi-
dates. Supplementary data are available with less stringent thresholds
(#1 >log2FC >1, q< 0.001; Table S2).
Validation of candidate genes
Many of the candidate genes identified as contributing to gain or loss of sus-
ceptibility to ciprofloxacin are confirmed by published reports (see the
Results and discussion). To confirm the TraDIS data and validate the
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predicted role of some of the candidate genes in S. Typhi gain of ciprofloxa-
cin susceptibility, five genes were selected from the list of candidates for
directed inactivation. The construction of these mutations was achieved
using the suicide vector method described previously.16 This method
involved the use of intermediate constructs and the generation of mutants
in independent duplication to confirm that the observed phenotype was
due to the constructed mutation and was not due to changes elsewhere in
the genome.
Relative MIC determinations
Determination of relative differences in the MICs of antibiotics between the
five constructed mutants and parent strain was performed in 96-well
microtitre plates using dilutions of ciprofloxacin, ofloxacin and nalidixic acid
in total volumes of 200lL of LB broth! aro mix (see above). Two-fold con-
centration increments were used for nalidixic acid, 1.5-fold for ciprofloxacin
and increments of 1.2, 1, 0.85, 0.65 and 0.5 mg/L were used for ofloxacin.
Bacteria were added to a concentration of about 105 cfu/mL and incubated
at 37C for 18 h. The lowest concentration at which there was no obvious
visible growth was taken as the MIC. MICs were determined for two
mutants generated independently for each gene under investigation, and
three separate MIC determinations were performed, with the modal value
being presented.
Results and discussion
Application of the TraDIS method to ciprofloxacin
susceptibility
Modification of high-throughput sequencing methodology allows
the relative numbers of each transposon mutant in a large mutant
pool to be determined.19–22 A pool of at least 1 million S. Typhi Ty2
derivative transposon mutants21 was grown with or without a sub-
MIC concentration (0.05 mg/L; about 1=5 % MIC) of ciprofloxacin,
and the differences in endpoint growth of the mutants between
the two conditions were observed. The average distance between
different transposon insertion sites is about 10 bp, so the whole
genome has been assayed at this level of resolution (Table S1). The
output data from these experiments are expressed as the number
of sequence reads that have an identical nucleotide sequence to a
particular location in the genome. With reference to the S. Typhi
Ty2 whole-genome annotation, the number of reads that locate
within each gene may then be deduced. Whilst most mutants
incorporate a single transposon insertion, each gene will, on
average, be represented by dozens of different mutants within
the mutant pool, and by hundreds to upwards of several tens
of thousands of nucleotide sequence reads (see the Materials
and methods). Because the assay was performed using a sub-
MIC concentration of ciprofloxacin that allowed many of the
mutants to grow, the genes identified are those that contribute
to a gain or loss of fitness within the mutant pool grown in these
conditions.
Efflux and porin genes involved in ciprofloxacin
susceptibility
Those genes identified (Tables 1 and 2) that are already known
to be involved in fluoroquinolone susceptibility11,29–31 serve to
validate the TraDIS methodology and confirm that the fitness
changes measured correlate with changes to ciprofloxacin
susceptibility. For example, the genes coding for the AcrAB–TolC
efflux transporter and the outer membrane porin OmpF were
identified by our data as being important for S. Typhi susceptibil-
ity to ciprofloxacin (Tables 1 and 2; Figure 1a), as shown previ-
ously.17,30,32–35
Another efflux complex in E. coli, EmrAB–TolC, confers reduced
susceptibility to several toxins,36 and this efflux complex is
negatively regulated by EmrR. Our data indicate that in S. Typhi
mutation of emrR conferred reduced susceptibility to ciprofloxacin
(Table 2), as would be expected if emrAB became overexpressed
due to loss of repression by EmrR. Mutations in emrA or emrB did
not themselves increase susceptibility to ciprofloxacin, suggesting
that emrAB-dependent efflux does not contribute significantly to
loss of ciprofloxacin susceptibility in the presence of other efflux
mechanisms. However, when overexpressed as a result of inser-
tions into the emrR repressor gene, emrAB-dependent efflux does
contribute to susceptibility, as has been observed also for
Salmonella enterica serovar Typhimurium.37
In E. coli, emrD codes for MDR protein D, an efflux transporter
with a wide range of structurally distinct substrates.38
Unexpectedly, in S. Typhi, mutations in emrD led to a gain in cipro-
floxacin susceptibility, a result which was highly statistically signifi-
cant (Table 2 and Figure 1b). This difference may be specific to
S. Typhi, or it may reflect the coordinated regulation of multidrug
efflux. It has been shown that disruption of efflux systems results
in up-regulation of others in response,39 and it is possible that
emrD knockout indirectly induces another ciprofloxacin exporter.
Regulator genes involved in ciprofloxacin susceptibility
In E. coli and S. Typhimurium, the AcrAB–TolC efflux system and
OmpF are regulated by the marA/soxS/robA regulon, and, in add-
ition, by ramA in S. Typhimurium, which is absent from E. coli.40,41
MarA and Rob are positive regulators of the AcrAB–TolC efflux sys-
tem, and MarA, in addition, is a negative regulator of the outer
membrane porin, OmpF.40 Our data indicated that marA and rob
insertion mutants of S. Typhi were more susceptible to ciprofloxa-
cin (Table 1), as expected if the regulation by these genes in
S. Typhi is similar to that for E. coli and S. Typhimurium.
Other regulators involved in expression of acrAB and tolC in-
clude acrR and marR, which were absent from our gene lists. In
our data, acrR had a log2FC of 1.0 (average 1500 read counts in
controls compared with 2800 for ciprofloxacin-treated cul-
tures) and was therefore removed by our criterion of #1.5
log2 FC 1.5, even though the q value for this gene was
7.4%10#30. Thus, the log2 FC limits employed to generate the
gene lists of Tables 1 and 2 will miss some genes that may con-
tribute to gain or loss of ciprofloxacin susceptibility, and acrR is
one such gene (Figure 1), but will provide a more robust list of
gene candidates.
FormarR, there was little difference in the number of nucleotide
sequence reads between the ciprofloxacin-treated and untreated
growth conditions (log2 FC = 1.0). However, following growth with
ciprofloxacin, there was an observable increase in the number of
transposon insertions oriented such that transcription from the
transposon kanamycin resistance gene could read through into
marAB (Figure 1c). The Bio-Tradis software suite generates statis-
tical data based on insertion sites on a gene-by-gene basis and,
although the orientation of the insertions is known (from the DNA
strand to which the nucleotide sequence reads locate), the soft-
ware does not use this information. The enrichment of inserts in
S. Typhi ciprofloxacin susceptibility JAC
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one orientation adjacent to genes supports the observation that
TraDIS can be used to predict impacts of altered gene expression
on phenotype.42
Genes involved in DNA binding and repair
Like other fluoroquinolone antibiotics, ciprofloxacin acts by binding
to DNA gyrase and topoisomerase IV, and results in DNA strand
Table 1. S. Typhi transposon insertion mutants displaying enhanced susceptibility to ciprofloxacina
Higher function Gene name Function Log2FC q value
b
Membrane/surface associated acrA acriflavin resistance protein A; AcrAB–TolC efflux #9.27 3.99% 10#74
acrB acriflavin resistance protein B; AcrAB–TolC efflux #6.85 2.6% 10#304
ybhT putative exported protein #3.24 9.99% 10#23
tolC outer membrane protein TolC; AcrAB–TolC efflux #3.01 1.78% 10#62
t3146 putative membrane protein #2.04 2.61% 10#58
t2964 putative membrane protein; conserved #1.86 3.43% 10#35
t3276 putative outer membrane protein; conserved #1.75 4.27% 10#12
mrcA penicillin-binding protein 1A #1.60 5.3% 10#49
plsC 1-acyl-glycerol-3-phosphate acyltransferase #1.57 1.03% 10#8
t3147 putative exported protein #1.50 3.08% 10#19
fliJ flagellar FliJ protein #1.41 5.86% 10#12
marB multiple antibiotic resistance protein MarB; periplasmic #1.41 5.15% 10#16
Regulators phoP transcriptional regulatory protein PhoP #3.00 4% 10#29
barA sensor protein #2.87 2.27% 10#62
marA multiple antibiotic resistance protein MarA #2.87 7.17% 10#50
tyrR transcriptional regulatory protein TyrR #2.86 9.74% 10#58
sirA invasion response-regulator #2.58 7.03% 10#7
cysB cys regulon transcriptional activator #2.54 3.3% 10#172
t3449 possible LysR-family transcriptional regulatory protein #2.51 5.59% 10#16
phoQ sensor protein PhoQ #1.94 4.78% 10#34
fadR fatty acid-fatty acyl responsive DNA-binding protein #1.55 4.87% 10#11
rob right origin-binding protein #1.41 2.88% 10#23
DNA repair/nucleoid associated hupA histone-like DNA-binding protein HU-alpha #3.57 2.66% 10#74
recN DNA repair protein #3.19 1.7% 10#20
xseA exodeoxyribonuclease large subunit #3.04 5.7% 10#64
sbcB exodeoxyribonuclease I #2.32 1.79% 10#85
t1056 putative ATP-dependent helicase #2.24 1.33% 10#52
hupB DNA-binding protein HU-beta #2.11 7.37% 10#19
endA endonuclease I #1.76 1.37% 10#31
recG ATP-dependent DNA helicase #1.69 3.17% 10#8
uvrD DNA helicase II #1.42 9.16% 10#17
Cell division nlpI lipoprotein; possibly cell division #3.41 3.07% 10#29
ftsN cell division protein #1.86 1.34% 10#5
dedD cell division protein #1.66 1.15% 10#9
ftsH cell division protein #1.43 9.56% 10#8
RNA/RNA processing trpS tryptophanyl-tRNA synthetase #2.36 8.06% 10#17
hfQ host factor-I protein #1.97 3.54% 10#40
micF small RNA regulator of ompF expression #1.87 9.39% 10#7
pnp polynucleotide phosphorylase #1.59 1.05% 10#10
Others t2965 conserved hypothetical protein #2.73 1.08% 10#21
t0625 tRNA-Pro #2.00 5.12% 10#11
t0533 putative aminotransferase #1.65 2.18% 10#9
ygdD conserved hypothetical protein #1.52 2.45% 10#7
aNucleotide sequence reads are generated specifically from transposon insertion sites and therefore precisely identify the site location. Log2FC refers
to the difference in nucleotide sequence reads that locate within a gene between a ciprofloxacin-treated and an untreated culture of a pool of at
least 1 million mutants. The number of nucleotide sequence reads that locate within a gene reflects the number of insertion mutants that are present
for that gene.19–22 The values are logarithms in base 2, so negative values indicate that the number of representative mutants is less for ciprofloxa-
cin-treated compared with untreated, and that these mutants have an enhanced susceptibility in these growth conditions.
bq values indicate the statistical significance of the data and are P values adjusted for the false discovery rate.27
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Table 2. S. Typhi mutants displaying diminished susceptibility to ciprofloxacin
Higher function Gene name Function Log2FC q value
Carbohydrate/polysaccharide
metabolism
pfkA 6-phosphofructokinase 2.30 1.02% 10#38
tviC Vi polysaccharide biosynthesis protein, epimerase 2.16 5.5% 10#198
rfbE CDP-tyvelose-2-epimerase 2.11 8.14% 10#94
waaI lipopolysaccharide 1,3-galactosyltransferase 2.01 8.1% 10#106
rfbU putative glycosyl transferase 1.97 1.01% 10#60
rfbM mannose-1-phosphate guanylyltransferase 1.97 8% 10#108
rfbK phosphomannomutase 1.94 2.5% 10#140
waaJ lipopolysaccharide 1,2-glucosyltransferase 1.85 7.27% 10#84
galE UDP-glucose 4-epimerase 1.83 3.38% 10#24
rffM probable UDP-N-acetyl-D-mannosaminuronic acid transferase 1.81 1.44% 10#51
rffD UDP-ManNAc dehydrogenase 1.75 1.99% 10#51
rfbI putative reductase RfbI 1.73 2.1% 10#105
mtlD mannitol-1-phosphate dehydrogenase 1.68 2.67% 10#72
nagA N-acetylglucosamine-6-phosphate deacetylase 1.68 1.82% 10#13
waaK lipopolysaccharide 1,2-N-acetylglucosaminetransferase 1.67 1.41% 10#97
waaL O-antigen ligase 1.61 3.88% 10#77
wecB UDP-N-acetyl-D-glucosamine 2-epimerase 1.59 4.44% 10#84
pgi glucose-6-phosphate isomerase 1.50 4.76% 10#77
rfbS paratose synthase 1.46 3.52% 10#6
Regulators slyA transcriptional regulator of haemolysin E 3.19 2.8% 10#111
emrR putative transcriptional regulator 2.86 5.9% 10#183
envZ two-component sensor kinase EnvZ 2.21 7.41% 10#12
cpxR envelope stress two-component response regulatory protein 2.09 1.48% 10#57
t1707 putative TetR-family regulatory protein 1.95 8.65% 10#88
phoU phosphate transport system regulatory protein 1.86 6.91% 10#14
nadR conserved hypothetical transcriptional regulator 1.75 1.3% 10#114
yijC possible TetR-family transcriptional regulatory protein 1.58 1.89% 10#33
cytR transcriptional repressor 1.57 2.17% 10#72
rseC sigma-E factor regulatory protein RseC 1.53 1.81% 10#26
crp cyclic AMP receptor protein, catabolite gene activator 1.51 2.55% 10#7
gntR gluconate utilization operon repressor 1.45 3.34% 10#33
gatR galactitol utilization operon repressor 1.45 1.37% 10#7
spf small regulatory RNA 1.45 1.81% 10#11
mtlR mannitol operon repressor 1.40 2% 10#47
Membrane/surface associated ompF outer membrane protein F precursor 3.91 0
t0641 putative outer membrane lipoprotein 2.77 7.4% 10#171
emrD multidrug resistance protein D 2.26 2.9% 10#185
dgkA diacylglycerol kinase 2.04 3.24% 10#16
ppk polyphosphate kinase 1.95 5.5% 10#169
lepB signal peptidase I 1.78 9.39% 10#7
trkH trk system potassium uptake protein 1.78 5.06% 10#30
t3816 putative secreted protein 1.69 3.59% 10#56
nucE putative secretion protein 1.57 7.26% 10#7
yabI DedA-family integral membrane protein 1.54 2.16% 10#25
yhdA putative lipoprotein 1.54 3.09% 10#64
t2427 hypothetical major facilitator family transport protein 1.47 6.28% 10#48
Redox associated gor glutathione reductase 2.95 6.5% 10#158
trxB thioredoxin reductase 1.62 8.04% 10#24
t1325 putative NADH reducing dehydrogenase 1.48 1.8% 10#52
gshB glutathione synthetase 1.42 7.99% 10#10
t1326 putative ferredoxin-like protein, cytoplasmic membrane 1.41 2.27% 10#17
Continued
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breaks.43,44 Hence, our whole-genome assay identified a number
of genes coding for functions involved in DNA repair, such as recN,
recG, uvrD and xseA (Table 1), which have been identified previous-
ly as contributing to diminished ciprofloxacin susceptibility in
E. coli.31 In addition, we identified hupA and hupB, which encode
the HU histone-like protein that binds to DNA recombination
and repair intermediates, protecting them from exonuclease
degradation.45 The HU protein is also known to control a regulon
encompassing approximately 8% of the E. coli genome46 and may
contribute to loss of ciprofloxacin susceptibility via several indirect
regulatory mechanisms.
Transposon insertions adjacent to genes coding for the
fluoroquinolone target proteins and RNA polymerase
genes
The ciprofloxacin targets, DNA gyrase and topoisomerase IV
enzymes, act to maintain DNA topology in the bacterial genome,
and their encoding genes (gyrA and gyrB for DNA gyrase, and parC
and parE for topoisomerase IV) are essential.21,42,47 Consequently,
transposon mutants of these genes are non-viable and are absent
from our transposon mutant library, with the result that few or no
sequence reads were identical to the nucleotide sequences of
these genes. As a result, the gyrA, gyrB and parE genes were
among the 12% of genes that were not assayed. However, there
was a significant increase in mutants with insertions in the parC
gene, indicating that these mutants displayed reduced susceptibil-
ity to ciprofloxacin. However, these insertion mutations were
within the last 6 bp of parC and were oriented such that the trans-
poson kanamycin resistance gene is reverse transcribed into parC
(Figure 1d). Transposon insertions this close to the end of the parC
gene probably do not result in inactivation, but may confer some
loss in susceptibility to ciprofloxacin due to altered expression of
parC, such as may occur through post-transcriptional gene silenc-
ing by RNA interference resulting from transcription of parC in the
reverse direction.48
Gene t3103 is known only as being conserved and hypothetical,
but mutant numbers for this gene increased relatively in
ciprofloxacin-treated cultures (Table 2). The t3103 gene is up-
stream of the parE gene, and these insertion mutations may mani-
fest their phenotype, at least in part, by modulating parE
expression rather than being a direct result of insertion into the
t3103 gene (Figure 1e).
For the rpoC gene, encoding the essential RNA polymerase
b0-subunit, as demonstrated by the absence of insertions across
most of the gene (Figure 1f), the number of mutants increased
relatively in the ciprofloxacin-treated cultures (Table 2). These
insertion mutations were within the last 45 bp of the 30 end of
the rpoC gene (Figure 1f). Insertions in this part of the gene are
unlikely to result in its inactivation, but probably manifest their
phenotype through alteration of rpoC expression. There is also
an increase in mutants with insertion 50 to the rpoB gene
(Figure 1f), indicating that these mutants, which probably
alter transcription of the rpoBC gene, also display diminished
ciprofloxacin susceptibility. RNA polymerase mutants have
been shown previously to influence ciprofloxacin susceptibility
Table 2. Continued
Higher function Gene name Function Log2FC q value
Nucleoid associated parC topoisomerase IV subunit A 1.97 5.61% 10#17
hns DNA-binding protein 1.51 1.14% 10#84
hepA probable ATP-dependent helicase HepA 1.50 1.72% 10#70
RNA/RNA processing rpoC DNA-directed RNA polymerase, beta’-subunit 1.69 3.2% 10#115
rne ribonuclease E 1.61 9.9% 10#22
Murein metabolism aspC aspartate aminotransferase 1.74 1.62% 10#5
dacA D-alanine carboxypeptidase 1.47 1.3% 10#72
metL aspartokinase II 1.45 2.31% 10#57
Others t3103 conserved hypothetical protein 2.76 9.4% 10#161
guaA GMP synthase 2.29 2.51% 10#14
yabC conserved hypothetical protein 2.22 2.04% 10#13
yojL thiamine biosynthesis protein 1.87 1.99% 10#68
efp elongation factor P 1.79 2.21% 10#11
t2640 conserved hypothetical protein 1.68 1.68% 10#14
gidA glucose inhibited division protein 1.68 1.84% 10#9
thdF thiophene and furan oxidation protein 1.61 8.66% 10#7
aphA class B acid phosphatase precursor 1.49 1.06% 10#33
thiS thiamine biosynthesis protein 1.47 2.07% 10#7
ybeA conserved hypothetical protein 1.44 1.83% 10#10
ubiB flavin reductase 1.44 1.1% 10#37
ybeB conserved hypothetical protein 1.42 7.29% 10#19
yhjJ putative zinc-protease precursor 1.41 5.29% 10#71
Refer to footnotes for Table 1. Positive values for log2FC indicate that the number of representative mutants for each gene is greater for ciprofloxacin-
treated compared with untreated, and that these mutants therefore have diminished ciprofloxacin susceptibility in these growth conditions.
Turner et al.
6 of 10
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/advance-article-abstract/doi/10.1093/jac/dkaa204/5854851 by U
niversity of East Anglia user on 15 June 2020
by increasing MdtK-dependent efflux,49 and our data suggest
that a subtle change in susceptibility may be achieved by modu-
lation of RNA polymerase expression.
Surface polysaccharide biosynthesis genes involved in
ciprofloxacin susceptibility
Our experiments also identified at least 19 genes involved in poly-
saccharide and/or carbohydrate metabolism, in which transposon
insertions reduced ciprofloxacin susceptibility (Table 2). Fifteen of
these are involved in surface polysaccharide biosynthesis, includ-
ing thewaa (formerly rfa) genes I, J, K andwaaL, coding for biosyn-
thesis of the LPS outer core, and the LPS O-antigen biosynthetic
genes rfbE, I, K, M, S and rfbU. Also included were the galE gene
involved in UDP-galactose synthesis required both for LPS outer
core and O-antigen. Other genes included those involved in the
biosynthesis of enterobacterial common antigen (ECA), rffM, rffD
and wecB,50 and tviC required for Vi-antigen biosynthesis.51 There
control1
control2
CIP1
CIP2
acrR acrA acrB yhaJ
marB marA
parE icc rpoC ArplL JrpoBt3103
marC plsC parC t3096 t3098 t3099marR
emrD t3720t3718
control1
control2
CIP1
CIP2
control1
control2
CIP1
CIP2
(a) (b)
(c) (d)
(e) (f)
Figure 1. Mutant changes across some genetic locations following growth supplemented with ciprofloxacin. Distribution of nucleotide sequence
reads generated by TraDIS at six different S. Typhi genetic loci following growth supplemented with and without ciprofloxacin, viewed using
Artemis.56 At the bottom of each panel, genetic maps indicate the positions of the genes coded by the forward (dark grey) or reverse (light grey) DNA
strands. Above each genetic map are four location and quantification plots, one for each duplicate experiment treated with ciprofloxacin (CIP1 and
CIP2) or untreated (control1 and control2). Duplicates indicate the experimental reproducibility. Within the plots, fine vertical bars indicate the loca-
tion of transposon insertion sites, with the length of the bar proportional to the number of nucleotide sequence reads (and therefore the relative
number of mutants) that locate with that insertion site. Bars extending above the central axis indicate transposon insertion mutations oriented such
that the kanamycin resistance determinant encoded by the transposon is transcribed in the left to right direction, and those below indicate the re-
verse orientation. (a) Transposon insertions within the acrAB genes coding for efflux are lost in the presence of ciprofloxacin, whilst mutants with
insertions in the acrR gene, which codes for a repressor of acrAB, increase in numbers (log2FC = 1, i.e. by 2-fold). (b) Increased transposon mutants for
the EmrD efflux system following growth in the presence of ciprofloxacin. (c) Increased insertion mutants in the marA repressor, marR, following
growth with ciprofloxacin, oriented in the reverse direction such that transcriptional readthrough from the transposon will be into the marA gene;
also reduced mutants in marB. (d) Insertions within the last codon of parC increase in the presence of ciprofloxacin, as indicated by an increase in the
height of the bar extended above the central axis at this location. These insertions are oriented such that the transposon kanamycin resistance gene
may reverse transcribe into the parC gene and thereby modulate expression through RNA interference. The bar extended below the central axis in
this location is immediately outside of the parC gene. (e) Increased transposon insertions within the t3103 gene with ciprofloxacin treatment may
lead to altered expression of the parE gene coding for a subunit of topoisomerase IV, which is the secondary target of ciprofloxacin. (f) Transposon
insertions into the last 25 bp of the rpoC, as well as immediately upstream of both rpoB and rpoC, increase with ciprofloxacin, suggesting that altered
expression of DNA polymerase may play a role in susceptibility.
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are previous reports of LPS mutations resulting in changed suscep-
tibility to fluoroquinolones, but our data provide a more compre-
hensive set of genes, and are the first to suggest a role for ECA and
Vi-antigen.17,30,34,52
Construction of mutants to validate candidate genes
involved in diminished ciprofloxacin susceptibility
To confirm the validity of predictions from the TraDIS data, dele-
tion mutations were constructed in the S. Typhi WT26 parent strain
for the hupA, tyrR, phoP, uvrD and xseA genes, identified as candi-
dates involved in ciprofloxacin susceptibility. All mutants showed a
reduced MIC of ciprofloxacin, though the changes were small
(Table 3). The mutants also showed a very small reduction in the
MIC of the fluoroquinolone, ofloxacin, and the naphthyridone,
nalidixic acid, which acts on GyrA in a similar way to the fluoroqui-
nolones (Table 3). Both uvrD and xseA have been identified previ-
ously as being involved in ciprofloxacin susceptibility in E. coli.31
These results complement previous reports validating the
TraDIS data and demonstrate their sensitivity for identifying loci
involved in antibiotic susceptibility and other stressors. Whilst the
phenotypic changes observed were small, these were for inser-
tional inactivation mutations, and greater phenotypic changes
may result from different types, or combinations, of mutation at
these same loci.
None of the pHCM1-encoded genes contributed to
ciprofloxacin susceptibility
Many MDR strains of S. Typhi circulating in Southeast Asia harbour
plasmid pHCM1 or similar derivatives.25,26 Thus, this plasmid was
transferred into our S. Typhi Ty2-derived strain for TraDIS analysis
experiments by conjugation. Plasmid pHCM1 is 218 kb and has 251
annotated genes, and our data indicate that none of these pHCM1-
encoded genes contributes significantly to ciprofloxacin susceptibility.
Concluding remarks
The continuing evolution of antibiotic resistance in clinically import-
ant human pathogens reduces treatment options for clinicians. A
better understanding of the mechanisms of antibiotic resistance
may provide opportunities for the identification of agents and im-
plementation of practices to counter resistance, and it may also en-
able the prediction of when and where resistance will arise.53
By combining a very large transposon mutant library with a
modified protocol for high-throughput nucleotide sequencing,21
we have screened about 88% of the genes in the genome of an S.
Typhi Ty2 derivative for a role in the gain or loss of susceptibility to
ciprofloxacin. However, most essential genes in which transposon
insertions are not tolerated have not been assayed including, for
example, recA, which is essential in S. Typhi but may also contrib-
ute to fluoroquinolone susceptibility.21,54 Whilst we have identified
these genes by using insertional inactivation mutation, and, in the
cases that we tested, MIC changes were small (Table 3), it is logical
to consider that other types of mutations (for example, base or
expression changes) in these same genes could also enhance or
diminish the phenotype to a greater or lesser extent. Thus, using a
whole-genome screen, we have found simultaneously many of
the fluoroquinolone susceptibility mechanisms that have taken
the previous decades to identify for E. coli and Salmonella, and
new mechanisms, including those associated with genes of previ-
ously unknown function and phenotype, thus providing the first
clues to their roles in bacterial biology.
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